- Home
- GYRE vs GRC Comparison
GYRE vs GRC Comparison
Compare GYRE & GRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- GRC
- Stock Information
- Founded
- GYRE 2002
- GRC 1933
- Country
- GYRE United States
- GRC United States
- Employees
- GYRE N/A
- GRC N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- GRC Fluid Controls
- Sector
- GYRE Health Care
- GRC Industrials
- Exchange
- GYRE Nasdaq
- GRC Nasdaq
- Market Cap
- GYRE 1.1B
- GRC 1.0B
- IPO Year
- GYRE N/A
- GRC N/A
- Fundamental
- Price
- GYRE $10.95
- GRC $37.60
- Analyst Decision
- GYRE
- GRC
- Analyst Count
- GYRE 0
- GRC 0
- Target Price
- GYRE N/A
- GRC N/A
- AVG Volume (30 Days)
- GYRE 129.2K
- GRC 64.9K
- Earning Date
- GYRE 11-13-2024
- GRC 02-07-2025
- Dividend Yield
- GYRE N/A
- GRC 1.97%
- EPS Growth
- GYRE N/A
- GRC 33.88
- EPS
- GYRE N/A
- GRC 1.45
- Revenue
- GYRE $105,033,000.00
- GRC $657,528,000.00
- Revenue This Year
- GYRE $25.32
- GRC $1.05
- Revenue Next Year
- GYRE $12.95
- GRC $3.60
- P/E Ratio
- GYRE N/A
- GRC $25.88
- Revenue Growth
- GYRE N/A
- GRC 1.95
- 52 Week Low
- GYRE $8.26
- GRC $30.47
- 52 Week High
- GYRE $26.37
- GRC $43.79
- Technical
- Relative Strength Index (RSI)
- GYRE 48.93
- GRC 43.39
- Support Level
- GYRE $9.51
- GRC $35.48
- Resistance Level
- GYRE $11.11
- GRC $37.97
- Average True Range (ATR)
- GYRE 0.85
- GRC 0.81
- MACD
- GYRE 0.04
- GRC 0.09
- Stochastic Oscillator
- GYRE 29.33
- GRC 66.30
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.